LumiThera Reports P-III Trial (LIGHTSITE III) Results of Valeda Light Delivery System for Dry Age-Related Macular Degeneration
Shots:
- The 24mos. results from the P-III trial (LIGHTSITE III) evaluating Photobiomodulation (PBM) using the Valeda Light Delivery System vs Sham treatment in a ratio (2:1) in 100 patients at 10 leading US retinal centers
- The results showed a sustained & significant improvement in BCVA @13mos. mean increase in ETDRS letter score >5.0 letters from baseline at 13 & 21mos., an improvement from baseline in BCVA @24mos. greater over the sham group, ~58% of the PBM-treated eyes had >5 letter gain with a mean of 8.5 + 0.5 letter gain
- Additionally, significant visual acuity improvement @12mos. The 24mos. OCT data showed that 5.7% vs 21.6% had progressed to new GA which demonstrated an excellent safety & clinical benefit profile
Ref: Businesswire | Image: LumiThera
Related News:- Abbott Reports Five Year Results of Mitraclip Device for the Treatment of Mitral Regurgitation
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
